957211-45-9Relevant academic research and scientific papers
Design, synthesis, and biological evaluation of (2R,αS)-3,4-dihydro- 2-[3-(1,1,2,2-tetrafluoroet-hoxy)phenyl]-5-[3-(trifluoromethoxy)-phenyl] -a-(trifluoromethyl)-1(2H)-quinolineethanol as potent and orally active cholesteryl ester transfer protein inhibi
Kuo, Gee-Hong,Rano, Thomas,Pelton, Patricia,Demarest, Keith T.,Gibbs, Alan C.,Murray, William V.,Damiano, Bruce P.,Connelly, Margery A.
, p. 1768 - 1772 (2009)
With the goal of identifying a CETP inhibitor with high in vitro potency and optimal in vivo efficacy, a conformationally constrained molecule was designed based on the highly potent and flexible 13. The synthetic chemistry efforts led to the discovery of
Improved asymmetric synthesis of 3,4-dihydro-2-[3-(1,1,2,2- tetrafluoroethoxy)phenyl]-5-[3-(trifluoromethoxy)phenyl]-α- (trifluoromethyl)-1(2H)-quinolineethanol, a potent cholesteryl ester transfer protein inhibitor
Rano, Thomas A.,Kuo, Gee-Hong
supporting information; experimental part, p. 2812 - 2815 (2009/12/05)
The asymmetric synthesis of 3,4-dihydro-2-[3-(1,1,2,2-tetrafluoroethoxy) phenyl]-5-[3-(trifluoromethoxy)phenyl]-α-(trifluoromethyl)-1(2H) -quinolineethanol (compound 11), a cholesteryl ester transfer protein inhibitor, Is accomplished. The asymmetric cent
1,2,3,4-TETRAHYDRO-QUINOLINE DERIVATIVES AS CETP INHIBITORS
-
Page/Page column 25; 29, (2008/06/13)
The invention is directed to compounds of Formula (I) described herein useful as CETP inhibitors, compositions containing them, and methods of using them.
